EP4234547A3 - Pharmaceutical salts of pyrimidine derivatives and method of treating disorders - Google Patents

Pharmaceutical salts of pyrimidine derivatives and method of treating disorders Download PDF

Info

Publication number
EP4234547A3
EP4234547A3 EP23179346.4A EP23179346A EP4234547A3 EP 4234547 A3 EP4234547 A3 EP 4234547A3 EP 23179346 A EP23179346 A EP 23179346A EP 4234547 A3 EP4234547 A3 EP 4234547A3
Authority
EP
European Patent Office
Prior art keywords
pyrimidine derivatives
pharmaceutical salts
treating disorders
present disclosure
polymorphic forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23179346.4A
Other languages
German (de)
French (fr)
Other versions
EP4234547A2 (en
Inventor
Landon J. DURAK
Marianne Langston
Pradeep Kumar Sharma
Thai Hiep Nguyen
Shuanglian LI
Xiaoguang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of EP4234547A2 publication Critical patent/EP4234547A2/en
Publication of EP4234547A3 publication Critical patent/EP4234547A3/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present disclosure relates to pharmaceutical salts and polymorphic forms of pyrimidine derivatives that have inhibitory activities against mutant epidermal growth factor receptor (EGFR). The present disclosure further relates to the processes for the preparation of the pyrimidine derivatives and to the pharmaceutical salts and the polymorphic forms of the pyrimidine derivatives.
EP23179346.4A 2018-05-14 2019-05-13 Pharmaceutical salts of pyrimidine derivatives and method of treating disorders Pending EP4234547A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862671182P 2018-05-14 2018-05-14
US201862671166P 2018-05-14 2018-05-14
EP19804043.8A EP3793993A4 (en) 2018-05-14 2019-05-13 Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
PCT/US2019/032002 WO2019222093A1 (en) 2018-05-14 2019-05-13 Pharmaceutical salts of pyrimidine derivatives and method of treating disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP19804043.8A Division EP3793993A4 (en) 2018-05-14 2019-05-13 Pharmaceutical salts of pyrimidine derivatives and method of treating disorders

Publications (2)

Publication Number Publication Date
EP4234547A2 EP4234547A2 (en) 2023-08-30
EP4234547A3 true EP4234547A3 (en) 2023-11-01

Family

ID=68540756

Family Applications (2)

Application Number Title Priority Date Filing Date
EP19804043.8A Pending EP3793993A4 (en) 2018-05-14 2019-05-13 Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
EP23179346.4A Pending EP4234547A3 (en) 2018-05-14 2019-05-13 Pharmaceutical salts of pyrimidine derivatives and method of treating disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP19804043.8A Pending EP3793993A4 (en) 2018-05-14 2019-05-13 Pharmaceutical salts of pyrimidine derivatives and method of treating disorders

Country Status (11)

Country Link
US (1) US20210309640A1 (en)
EP (2) EP3793993A4 (en)
JP (2) JP2021523208A (en)
KR (1) KR20200144579A (en)
CN (1) CN112313223A (en)
AU (1) AU2019269372A1 (en)
BR (1) BR112020023107A2 (en)
CA (1) CA3099737A1 (en)
MX (1) MX2020012063A (en)
TW (1) TWI831780B (en)
WO (1) WO2019222093A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020190119A1 (en) 2019-03-19 2020-09-24 주식회사 보로노이 Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
WO2020233669A1 (en) * 2019-05-22 2020-11-26 上海翰森生物医药科技有限公司 Indole derivative-containing inhibitor, preparation method therefor and application thereof
CN111303125A (en) * 2020-04-10 2020-06-19 天津法莫西医药科技有限公司 Methoxy-substituted indole-pyrimidine compound and preparation method thereof
WO2023277172A1 (en) 2021-06-30 2023-01-05 Takeda Pharmaceutical Company Limited Process for preparing pharmaceutical salts of pyrimidine derivatives
EP4367116A1 (en) * 2021-07-07 2024-05-15 Crimson Biopharm Inc. Crystalline polymorphs of epidermal growth factor receptor inhibitor, and compositions and methods thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195228A1 (en) * 2014-06-19 2015-12-23 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR020114A1 (en) 1998-07-30 2002-04-10 America Home Products Corp PROCESS FOR PREPARATION OF SUBSTITUTED QUINAZOLINE DERIVATIVES AND COMPOUNDS FOR ITS EXCLUSIVE USE IN THIS PROCESS
JP2003519698A (en) * 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ，インコーポレイテッド High-throughput formation, identification and analysis of various solid forms
GB0311274D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
EP2440559B1 (en) * 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
CN106995437A (en) * 2016-01-22 2017-08-01 齐鲁制药有限公司 Substituted indole or indazole pyrimidine derivatives and its production and use
ES2924522T3 (en) * 2016-09-12 2022-10-07 Padlock Therapeutics Inc Heteroaryl inhibitors of PAD4

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195228A1 (en) * 2014-06-19 2015-12-23 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HILFIKER R.: "Polymorphism in the Pharmaceutical Industry", January 2006, WILEY-VCH VERLAG GMBH, Weinheim, ISBN: 978-3-527-31146-0, article HILFIKER R, BLATTER F., VON RAUMER M.: "Relevance of Solid-state Properties for Pharmaceutical Products", pages: 1 - 19, XP002528052 *
MINO R CAIRA ED - MONTCHAMP JEAN-LUC: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY; [TOPICS IN CURRENT CHEMISTRY], SPRINGER, BERLIN, DE, vol. 198, January 1998 (1998-01-01), pages 163 - 208, XP008166276, ISSN: 0340-1022, [retrieved on 19990226], DOI: 10.1007/3-540-69178-2_5 *

Also Published As

Publication number Publication date
EP4234547A2 (en) 2023-08-30
JP2021523208A (en) 2021-09-02
JP2024051160A (en) 2024-04-10
KR20200144579A (en) 2020-12-29
EP3793993A4 (en) 2022-01-05
MX2020012063A (en) 2021-04-13
WO2019222093A1 (en) 2019-11-21
US20210309640A1 (en) 2021-10-07
BR112020023107A2 (en) 2021-02-02
AU2019269372A1 (en) 2020-11-26
TWI831780B (en) 2024-02-11
CN112313223A (en) 2021-02-02
CA3099737A1 (en) 2019-11-21
EP3793993A1 (en) 2021-03-24
TW202015687A (en) 2020-05-01

Similar Documents

Publication Publication Date Title
EP4234547A3 (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
ZA202202097B (en) Amino pyrimidine ssao inhibitors
CA2962914C (en) Compounds and compositions for modulating egfr mutant kinase activities
MX2019009501A (en) Amino pyrimidine compounds useful as ssao inhibitors.
WO2017108723A3 (en) PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
EA201790921A1 (en) SUBSTITUTED DERIVATIVES OF 2-ANILINPYRIMIDIN AS EGFR MODULATORS
MX361802B (en) Heteroaryl compounds for kinase inhibition.
AU2020255100A8 (en) N-heteroaromatic amide derivatives for treatment of cancer
SG10201902206QA (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
EP4275755A3 (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
MX2016007371A (en) 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimid in-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof.
NO20076093L (en) Substituted amide derivatives as protein kinase inhibitors
WO2010129053A8 (en) Egfr inhibitors and methods of treating disorders
WO2020141419A3 (en) Novel salts and polymorphic form of bempedoic acid
EA202090383A1 (en) IMPROVED METHOD FOR PRODUCING AMINOPYRIMIDINE DERIVATIVES
PH12020500093A1 (en) Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
MX2018005140A (en) Pyrimidine compositions, ultra-pure compositions and salts thereof, methods of making the same, and methods of using the same for treating histamine h4 receptor (h4) mediated diseases and conditions.
WO2020112941A3 (en) Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof
MX2022005749A (en) Allosteric egfr inhibitors and methods of use thereof.
PH12020550228A1 (en) Epidermal growth factor receptor inhibitors
EP4057471A4 (en) Photovoltaic system, optimizer and method for adjusting working state of optimizer
NZ742785A (en) Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
SA520411120B1 (en) Novel intermediates useful for the synthesis of aminopyrimidine derivatives, process for preparing the same, and process for preparing aminopyrimidine derivatives using the same
EP4046686A4 (en) Salt types, crystal forms, and preparation methods for benzopyrazole compounds as rho kinase inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3793993

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20230925BHEP

Ipc: C07C 55/10 20060101ALI20230925BHEP

Ipc: C07D 403/04 20060101AFI20230925BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40096550

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240501

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR